URGN UroGen Pharma Ltd.

16.5
-1.34  -8%
Previous Close 17.84
Open 17.3
Price To Book 1.94
Market Cap 349,056,923
Shares 21,154,965
Volume 168,556
Short Ratio
Av. Daily Volume 189,962
Stock charts supplied by TradingView

NewsSee all news

  1. UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development

    Experienced Leadership Team with Established Track Record Prepares for Transition to a Commercial Stage Organization UroGen Pharma Ltd. (NASDAQ:URGN) a biopharmaceutical company dedicated to building novel solutions

  2. Arkin Holdings Raises $140 Million in Second Partnership Arkin Bio-Ventures II to Invest in Groundbreaking Pharma and Biotechnology Companies

    - investors include Migdal and Phoenix Group – - New fund will invest in life sciences companies developing disruptive therapies in areas of high unmet medical need – Arkin Holdings, the largest and leading

  3. UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    UroGen Pharma Ltd. (NASDAQ:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants

  4. UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments

    Prescription Drug User Fee Act (PDUFA) Goal Date of April 18th for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Experienced Commercial Team Hired and Prepared for Planned UGN-101 Approval

  5. UroGen Pharma Announces March 2020 Investor Conference Schedule

    UroGen Pharma Ltd. (NASDAQ:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial ongoing.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Phase 3 trial planned for 2H 2020.
VesiGel UGN-102
Low grade non-muscle invasive bladder cancer (LG-NMIBC)
PDUFA date under priority review April 18, 2020.
MitoGel - UGN-101
Urothelial Carcinoma

Latest News

  1. UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development

    Experienced Leadership Team with Established Track Record Prepares for Transition to a Commercial Stage Organization UroGen Pharma Ltd. (NASDAQ:URGN) a biopharmaceutical company dedicated to building novel solutions

  2. Arkin Holdings Raises $140 Million in Second Partnership Arkin Bio-Ventures II to Invest in Groundbreaking Pharma and Biotechnology Companies

    - investors include Migdal and Phoenix Group – - New fund will invest in life sciences companies developing disruptive therapies in areas of high unmet medical need – Arkin Holdings, the largest and leading

  3. UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    UroGen Pharma Ltd. (NASDAQ:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants

  4. UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments

    Prescription Drug User Fee Act (PDUFA) Goal Date of April 18th for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Experienced Commercial Team Hired and Prepared for Planned UGN-101 Approval

  5. UroGen Pharma Announces March 2020 Investor Conference Schedule

    UroGen Pharma Ltd. (NASDAQ:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will

  6. UroGen Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 2, 2020

    Conference Call and Webcast Scheduled for Monday, March 2, 2020 at 8:30 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and

  7. UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference

    UroGen Pharma Ltd. (NASDAQ:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that Liz

  8. UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101

    Potential for UGN 101 to be First Non-Surgical Therapy for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC) UroGen Pharma Ltd. (NASDAQ:URGN) today announced the U.S. Food and Drug Administration (FDA)

  9. UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units ("RSUs") to five

  10. UroGen to Present at November 2019 Investor Conferences

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will participate in fireside chats at the following

  11. UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

    Completed Submission of New Drug Application (NDA) to U.S. FDA for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Exclusive Worldwide License Agreement with Agenus to Advance Treatment of

  12. UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers

    UroGen to Develop and Commercialize Zalifrelimab (AGEN1884, anti-CTLA-4 antibody) with UGN-201 for High-Grade Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical

  13. UroGen Pharma to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    Conference Call and Webcast Scheduled for Tuesday, November 12, 2019 at 8:30 AM ET UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report third quarter 2019 financial results on Tuesday, November 12,

  14. UroGen To Present at October 2019 Investor Conference

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will present at the following conference in

  15. UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances

    UGN-101 and UGN-102 Demonstrate Positive Clinical Data in Low-Grade Upper Tract Urothelial Cancer (LG UTUC) and Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC) UGN-101 Final Data Modules for NDA Submission

  16. UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer

    UGN-101: Consistent Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12

  17. UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness

    Company to Also Participate in September Investor Conferences UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced

  18. UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units ("RSUs") to 15